Lymphoma - refractory follicular B-cell non-Hodgkin’s lymphoma

The Pharmaceutical Benefits Scheme (PBS) subsidises idelalisib for patients with refractory follicular B-cell non-Hodgkin’s lymphoma.

As this program is now on the general schedule, from 1 January 2022 this page is for informational purposes only.

Patient eligibility

The PBS subsidises treatment with idelalisib under the National Health Act 1953, section 85 for patients with refractory follicular B-cell non-Hodgkin’s lymphoma.

Patients must be eligible for the PBS and meet relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing idelalisib.

Authority applications

Applying for initial treatment

To apply for initial authority approval to prescribe PBS subsidised idelalisib to treat refractory follicular B-cell non-Hodgkin’s either:

Applying for continuing treatment

Continuing PBS subsidised treatment with idelalisib is Authority Required (Streamlined). It doesn’t need prior authority approval from us for listed quantities and repeats.

More information

Call the PBS authority approvals line for further information.

Page last updated: 3 March 2022